1.
N C Med J
; 66(6): 481-3, 2005.
Article
in English
| MEDLINE
| ID: mdl-16438109
2.
Invest New Drugs
; 9(3): 253-6, 1991 Aug.
Article
in English
| MEDLINE
| ID: mdl-1664423
ABSTRACT
Forty-six previously untreated patients with advanced non-small cell lung cancer (NSCLC) were entered into a Hoosier Oncology Group phase II trial of daily oral etoposide 50 mg/m2/d. The dose limiting toxicity was granulocytopenia. The non-hematologic toxicity was mild, with only 19% of patients developing Grade 3 or 4 leukopenia. Two partial responses of 10 and 16 weeks duration were seen in 43 evaluable patients, for an overall response rate of 4%. We conclude that daily oral etoposide has minimal activity in advanced NSCLC, and does not improve response rates over conventional 1-5 day intravenous etoposide administration.